Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
Perseghin P, Gambacorti-Passerini C, Tornaghi L, Dassi M, Pioltelli P, Parma M, Colnaghi F, Giudici G, Elli E, Fumagalli M, Ponchio L, Biondi A, Pogliani EM. Perseghin P, et al. Among authors: colnaghi f. Transfusion. 2005 Jul;45(7):1214-20. doi: 10.1111/j.1537-2995.2005.00175.x. Transfusion. 2005. PMID: 15987369
Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission.
Parma M, Viganò C, Fumagalli M, Colnaghi F, Colombo A, Mottadelli F, Rossi V, Elli E, Terruzzi E, Belotti A, Cazzaniga G, Pogliani EM, Pioltelli P. Parma M, et al. Among authors: colnaghi f. Mediterr J Hematol Infect Dis. 2015 Jun 1;7(1):e2015041. doi: 10.4084/MJHID.2015.041. eCollection 2015. Mediterr J Hematol Infect Dis. 2015. PMID: 26075048 Free PMC article.
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients.
Piazza RG, Magistroni V, Andreoni F, Franceschino A, Tornaghi L, Varella-Garcia M, Bungaro S, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. Piazza RG, et al. Among authors: colnaghi f. Leukemia. 2005 Nov;19(11):1985-7. doi: 10.1038/sj.leu.2403928. Leukemia. 2005. PMID: 16121215 No abstract available.
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. Piazza RG, et al. Among authors: colnaghi f. Blood Cells Mol Dis. 2006 Sep-Oct;37(2):111-5. doi: 10.1016/j.bcmd.2006.06.002. Epub 2006 Aug 14. Blood Cells Mol Dis. 2006. PMID: 16908206 Clinical Trial.
The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.
Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, de Weger R, van Loon J, de Vries L, Cavé H, Acquaviva C, Lawler M, Crampe M, Serra A, Saglio B, Colnaghi F, Biondi A, van Dongen JJ, van der Burg M, Gonzalez M, Alcoceba M, Barbany G, Hermanson M, Roosnek E, Steward C, Harvey J, Frommlet F, Bader P. Lion T, et al. Among authors: colnaghi f. Leukemia. 2012 Aug;26(8):1821-8. doi: 10.1038/leu.2012.66. Epub 2012 Mar 7. Leukemia. 2012. PMID: 22395360
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2).
Morello E, Arena F, Malagola M, Farina M, Polverelli N, Cavagna E, Colnaghi F, Donna L, Zollner T, Accorsi Buttini E, Andreoli M, Ricci C, Leoni A, Samarani E, Bertulli A, Leali D, Bernardi S, Russo D. Morello E, et al. Among authors: colnaghi f. Nutrients. 2022 Aug 31;14(17):3589. doi: 10.3390/nu14173589. Nutrients. 2022. PMID: 36079847 Free PMC article.
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol).
Malagola M, Turra A, Signorini L, Corbellini S, Polverelli N, Masina L, Del Fabro G, Lorenzotti S, Fumarola B, Farina M, Morello E, Radici V, Buttini EA, Colnaghi F, Bernardi S, Re F, Caruso A, Castelli F, Russo D. Malagola M, et al. Among authors: colnaghi f. Front Oncol. 2022 Jun 17;12:874117. doi: 10.3389/fonc.2022.874117. eCollection 2022. Front Oncol. 2022. PMID: 35785189 Free PMC article.
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review.
Accorsi Buttini E, Farina M, Lorenzi L, Polverelli N, Radici V, Morello E, Colnaghi F, Almici C, Ferrari E, Bianchetti A, Leoni A, Re F, Bosio K, Bernardi S, Malagola M, Re A, Russo D. Accorsi Buttini E, et al. Among authors: colnaghi f. Front Oncol. 2023 Jan 20;13:1036455. doi: 10.3389/fonc.2023.1036455. eCollection 2023. Front Oncol. 2023. PMID: 36741006 Free PMC article.
Timely Leukapheresis May Interfere with the "Fitness" of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients.
Farina M, Chiarini M, Almici C, Accorsi Buttini E, Zuccalà F, Piva S, Volonghi I, Poli L, Bernardi S, Colnaghi F, Re F, Leoni A, Polverelli N, Turra A, Morello E, Galvagni A, Moratto D, Brugnoni D, Cattaneo C, Ferrari E, Bianchetti A, Malagola M, Re A, Russo D. Farina M, et al. Among authors: colnaghi f. Cancers (Basel). 2022 Oct 27;14(21):5276. doi: 10.3390/cancers14215276. Cancers (Basel). 2022. PMID: 36358694 Free PMC article.
11 results